Ortho Clinical Diagnostics is an in vitro diagnostics company that makes products and diagnostic equipment for blood testing. Ortho serves two primary industries in the medical field: clinical laboratories, by producing platforms and assays that test for a variety of diseases, conditions, and substances; and immunohematology, by providing the means to ensure blood transfusion recipients receive appropriate and compatible blood. Johnson and Johnson acquired Eastman Kodak's Clinical Diagnostics Division in 1994 (to form Johnson & Johnson Clinical Diagnostics), which was then merged with Ortho Diagnostic Systems in 1997. Ortho's global corporate offices are in Raritan, New Jersey, while their global research and development center is in Rochester, New York.In 2014, The Carlyle Group purchased the company from Johnson & Johnson for $4.15 billion. Ortho Clinical Diagnostics now operated as an independent company, up until its acquisition by Quidel Corporation for $6 billion, on May 27th 2022.15 billion.
Effective clinical and public health decision-making during a pandemic depends on reliable and interoperable clinical diagnostic test results. To ensure trustworthy outcomes, we need widely available calibration standards harmonized to a shared scale. We present a “playbook” for an interlaboratory harmonization study that calibrates any available standards against a limited-availability standard issued by a global authority like the World Health Organization (WHO).
Abstract Background The study objectives were: 1) establish 99th percentile upper reference limits (URL) for the VITROS™ Immunodiagnostic Products hs Troponin I (VITROS hsTnI) Assay, 2) confirm VITROS hsTnI Assay meets analytical performance criteria for a high-sensitivity cardiac troponin assay established by the IFCC Task Force on Cardiac Bio-markers (TF-CB), and 3) evaluate clinical performance for aiding in diagnosis of myocardial infarction (MI). Methods Overall and sex-specific 99th percentile URLs were established with lithium heparin plasma samples from a healthy U.S. reference population (N = 952, aged 22–91 years) including 486 females and 466 males. Subjects were pre-screened via questionnaire, followed by biomarker-based screening per IFCC TF-CB recommendations. VITROS hsTnI Assay results were assessed to verify detectable troponin concentrations at or above the limit of detection (LoD [0.59 ng/L]) in >=50% of healthy males and females. Analytical imprecision (% coefficient of variation [%CV]) was determined at overall and sex-specific cutoffs. The clinical performance study enrolled subjects 22 years and older, presenting with symptoms consistent with acute coronary syndrome at 24 U.S. emergency departments (ED). Each subject’s diagnosis was determined by an independent adjudication committee consisting of cardiologists and according to the Fourth Universal Definition of Myocardial Infarction. Serial lithium heparin plasma specimens were tested with VITROS hsTnI Assay in four time brackets relative to patients’ ED presentation (0–2 hours, >=2–4 hours, >=4–6 hours, and >=6–11 hours). Sensitivity, specificity, positive and negative predictive values (PPV and NPV) were determined for each time bracket. Testing was performed on VITROS 5600 Integrated System. Comparable assay performance has been demonstrated across VITROS 3600 Immunodiagnostic and XT 7600 Integrated Systems. Results The overall 99th percentile URL was determined to be 11 ng/L (90% CI, 8.2–14.3 ng/L); the female-specific URL was 9 ng/L (90% CI, 3.9–17.5 ng/L); and the male-specific URL was 12 ng/L (90% CI, 8.8–20.9 ng/L). Analytical imprecision was 4.7%CV at the female-specific URL, 4.5%CV at the male-specific URL, and 4.5%CV at the overall URL. VITROS hsTnI Assay detected troponin concentrations at or above the LoD in 659/952 healthy subjects (69.2%), 282/486 (58.0%) females and 377/466 (80.9%) males. The prevalence of adjudicated MI in the study was 8.16% (175/2145). Using the overall URL, clinical sensitivity of VITROS hsTnI Assay for all subjects ranged from 85.64%–93.30% across all time brackets. Specificity ranged from 78.55%–86.60%. NPVs were >=98.57% and PPVs ranged from 35.80%–40.14%. For females, using the sex-specific URL, sensitivity and specificity ranged from 88.71–97.62% and 84.76–90.31%, respectively. NPV was >99% for all time brackets while PPV ranged from 36.67–45.11%. For males, sensitivity and specificity ranged from 84.03–93.16% and 75.07–83.11%, respectively. NPVs were >=97.95% and PPVs ranged from 35.06–39.07%. Conclusion The VITROS hsTnI Assay meets the analytical performance criteria for a high-sensitivity cardiac troponin assay, demonstrating acceptable precision at the 99th percentile URLs and detection rates >50% in a healthy reference population. The clinical performance assessment demonstrated the assay effectively aids in diagnosis of MI in a U.S. population when used in conjunction with other clinical information.
Abstract Background Progesterone can be used as an aid in the diagnosis and treatment of disorders of the ovaries or placenta. Designed with a sheep monoclonal antibody rather than a polyclonal rabbit antibody, the VITROS Immunodiagnostic Products (VITROS Progesterone 2) Assay is a next-generation immunoassay developed to improve analytical specificity through key reagent redesign to replace the VITROS Immunodiagnostic Products Progesterone Assay. The assay employs a sheep monoclonal antibody, biotinylated and overcoated onto streptavidin-coated wells to mitigate susceptibility to biotin interference. Studies were conducted to evaluate the analytical performance of the VITROS Progesterone 2 Assay by determining limit of quantitation (LoQ) and precision. A method comparison study of the VITROS Progesterone 2 Assay with the Roche Elecsys Progesterone III assay was also conducted. Methods The LoQ was determined consistent with CLSI document EP17. Precision was determined consistent with CLSI EP05. Repeatability (within-run) percent coefficient of variation (%CV) was determined using two replicates per run. Reproducibility (within-lab) %CV was determined using a single reagent lot and a single calibration. A quantitative comparison between the VITROS Progesterone 2 Assay and the Roche Elecsys Progesterone III assay was performed in accordance with CLSI guideline EP09 using 125 serum samples. The VITROS Progesterone 2 Assay was screened for interfering substances at progesterone concentrations of approximately 3.00 ng/mL, and 12.0 ng/mL following CLSI EP07 12 and EP37. Results The claimed LoQ was determined using a precision profile approach with a %CV limit of 20% and set at 0.335 ng/mL. Precision was observed at low, intermediate and high regions of the measuring interval. At a progesterone concentration of approximately 0.9 ng/mL, repeatability was 4.5%CV and reproducibility was 6.4%CV. At a progesterone concentration of approximately 19.5 ng/mL, repeatability was 1.7%CV and reproducibility was 2.5%CV. At a progesterone concentration of approximately 35 ng/mL, repeatability was 1.8%CV and reproducibility was 2.7%CV. The method comparison between the VITROS Progesterone 2 Assay and the Roche Elecsys Progesterone III assay yielded a correlation coefficient of 0.995 and a Passing-Bablok slope of 0.99 and intercept of -0.47. Interference testing demonstrated no biotin interference effect on assay performance at concentrations up to 3,510 pg/mL. Conclusion The VITROS Progesterone 2 Assay demonstrated acceptable analytical performance across evaluated parameters including precision and limit of quantitation, with very high correlation and close agreement to the Roche Elecsys Progesterone III assay.
Background: Clindamycin phosphate 1.2%/adapalene 0.15%/benzoyl peroxide 3.1% (CAB) gel demonstrated efficacy in the treatment of acne, with a good safety/tolerability profile, in participants with moderate to severe acne. Acne clinical presentation and response to treatment may differ between males and females as well as between pediatric-postadolescent (<24 years) and adult (≥25 years) patients. The objective of this post hoc analysis was to evaluate the impact of age and sex on the efficacy and safety of CAB gel. Methods: In one phase 2 and two phase 3 double-blind, 12-week studies, participants with moderate-to-severe acne were randomized to once-daily CAB or vehicle (Veh). Data were analyzed post hoc for participants categorized by age and sex: females 9-24 or ≥25 years (ns=274 and 121) and males 9-24 or ≥25 years (ns=241 and 21). Efficacy endpoints included treatment success (percentage of participants achieving ≥2-grade reduction from baseline in Evaluator’s Global Severity Score and a score of 0 or 1 [clear/almost clear]) and reductions from baseline in inflammatory and noninflammatory lesions (IL/NIL). Treatment-emergent adverse events (TEAEs) were also assessed. Results: At week 12, a greater percentage of participants in all sex/age subgroups achieved treatment success with CAB (42.3-54.1%) than Veh (15.0-22.5%). Similarly, lesion reductions were larger with CAB than Veh (IL: CAB, 75.9-77.8%; Veh, 50.8-65.2%; NIL: CAB, 69.7-73.7%; Veh, 44.5-55.2%). For all efficacy endpoints, CAB was statistically superior to Veh among males and females 9-24 years and females ≥25 years (P≤0.05, all). For males ≥25 years, only NIL reductions were significantly greater with CAB (P≤0.05), likely due to the small population. For all CAB-treated groups, most TEAEs were of mild-moderate severity. Rates of TEAEs deemed related to CAB treatment were similar for males and females 9-24 years (19.7% and 18.6%, respectively) and somewhat higher for females ≥25 years (24.4%). Considerably lower treatment-related TEAE rates in males ≥25 years (8.3%) may reflect the low number of participants in this group (n=12 treated with CAB). Conclusions: In 3 clinical trials, participants treated with CAB gel—the only fixed-dose, triple-combination topical for acne—experienced ≥70% lesion reductions, and approximately half achieved clear or almost clear skin. CAB gel demonstrated good efficacy and tolerability regardless of participants’ sex or age. Funding: Ortho Dermatologics
Background: Toenail onychomycosis treatment is challenging, especially in older adults, due to slower nail growth, increased nail thickness, and greater likelihood of concomitant medication use and comorbidities (eg, diabetes, peripheral vascular disease, reduced renal function). Unfortunately, published efficacy and safety data in older adults are limited. Efinaconazole 10% solution has demonstrated efficacy and favorable tolerability in two phase 3 studies and in post hoc analyses of participant sex, ethnicity, age, baseline disease severity, and concurrent diabetes. Here, pooled post hoc analyses were conducted to evaluate efficacy and safety of efinaconazole in participants aged ≥65 years with mild to moderate onychomycosis. Methods: Data were pooled from 2 multicenter, randomized, double-blind, vehicle-controlled phase 3 studies (NCT01008033, NCT01007708) of participants aged 18-70 years with mild to moderate distal lateral subungual onychomycosis affecting ≥1 great toenail. Participants (n=1,655) were randomized (3:1) to topical efinaconazole 10% or vehicle applied once daily for 48 weeks, with a follow-up visit at week 52. Efficacy endpoints included rates of complete cure (0% clinical involvement of target toenail + negative potassium hydroxide [KOH] examination + negative fungal culture), mycologic cure (negative KOH + negative fungal culture), complete/almost complete cure (≤5% clinical involvement + mycologic cure), unaffected new toenail growth (change from baseline in unaffected toenail measurement), and clinical efficacy (<10% clinical involvement) at week 52. Adverse events (AEs) were also assessed. Only participants aged ≥65 years were included in these analyses (n=162 efinaconazole; n=56 vehicle). Results: At week 52, significantly more older adults treated with efinaconazole vs vehicle achieved a complete cure (13.6% vs 3.6%) or a complete/almost complete cure (19.1% vs 5.4%; P<0.05, both). Over half of participants treated with efinaconazole (59.2%) achieved mycologic cure vs 12.5% with vehicle (P<0.001). Least squares mean unaffected new nail growth was significantly greater with efinaconazole vs vehicle (3.9 mm vs 0 mm; P<0.001), and a quarter of participants achieved clinical efficacy with efinaconazole (25.3%) vs 14.3% with vehicle (P<0.05). Most treatment-emergent AEs with efinaconazole were mild to moderate in severity, and discontinuation rates were low (<4.5%), in line with the overall phase 3 populations. Conclusions: Topical efinaconazole 10% solution showed good efficacy and safety in participants aged ≥65 years with mild to moderate onychomycosis, despite possible age-related changes in nail growth. These results were in line with the overall phase 3 populations, demonstrating that efinaconazole is an efficacious treatment for older adults for whom there is a dearth of clinical data. Funding: Ortho Dermatologics